GENERIC
Divi's Labs shares jump 8% to fresh 52-week high after Q2 profit soars 64% YoY. What brokerages say after bumper results?
Divi’s Laboratories shares surged over 8% during Muhurat Trading, hitting a 52-week high after Q2 FY27 net profit jumped 64% to ₹1,127 crore. Revenue grew 35%, while brokerages differed on valuation concerns and future growth prospects.
For long- and medium-term investors: Cycles turn, principles don’t; 5 large-cap stocks with upside potential of up to 29%
These are the stocks that fell the most, so they may bounce back the most if the fund flows return. They are the ones FPI money will target first. And they tend to be the businesses with great track records, the ones that have been through bad patches like this before and have come out unscathed. Yes, we are talking about large-cap stocks.
More than family business: Drugmakers make costly, long-term strategic shifts as next generation steps into bigger roles
India's family-run pharmaceutical companies are entering a new phase as the next generation takes on larger leadership roles and steers businesses towards complex generics, peptides, biologics, contract manufacturing and advanced therapeutics. Laurus Labs, Granules India, Bharat Biotech, Sun Pharma and Torrent Pharma are investing in capabilities that require greater scientific expertise, significant capital and longer gestation periods. The key question is whether the successors can turn these long-term bets into sustainable growth and create lasting value for investors.
Pharma industry steps up API investments to cut import dependence, move up value chain
India's pharmaceutical sector is shifting towards high-value medicines and reducing reliance on imports through local manufacturing. Investments in active pharmaceutical ingredients and advanced therapies are on the rise to meet new healthcare demands. Industry leaders highlight the significance of supply-chain resilience and advancements in manufacturing capabilities. Recent data indicates strong domestic market growth and increasing pharmaceutical exports.
These large-, mid- and small-cap stocks have upside potential of up to 31% in 1 year, according to analysts
In the last two years, the world has learnt that you can never quite predict what US President Trump will do next. Tomorrow, to pull attention one way or another, there could well be some more action against Iran, changing the mood again in a single afternoon. So, the improvement in sentiment is real, but it is also fragile.
Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return
In 2026, India's pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic demand alongside enhanced profitability from new product launches. Notable players like Laurus Labs and Gland Pharma have recorded remarkable returns, topping 100%. Amid challenges faced by other sectors, the pharmaceutical field demonstrates resilience. Analysts are optimistic but advise exercising caution regarding potential market volatility and the durability of this sector's performance.
- Go To Page 1
Trump’s pain makes D-Street bulls gain! IndiGo, Asian Paints, other crude-sensitive stocks rally up to 8% as oil drops below $95
Paint makers, airlines, tyre companies and OMCs rallied as crude oil prices plunged nearly 10%, falling below $95 a barrel. Lower oil prices raised hopes of easing input and fuel costs, while Trump's midterm setback added to the positive market sentiment.
Dr Reddy's Laboratories receives ANVISA approval for generic semaglutide injection in Brazil
Dr Reddy’s Laboratories obtained marketing authorisation from Brazil’s ANVISA for a generic semaglutide injection. The product will be available as a pre-filled, multi-dose pen in two dosages for weekly administration. This drug targets treatment for type 2 diabetes alongside diet and exercise, particularly in patient groups needing alternative therapies. Brazil's diabetes prevalence creates significant market demand, estimated at approximately $244.6 million.
Biocon CEO forecasts H2 results to outperform H1; company posts 52% fall in Q2 net profit; revenue up 2%
Biocon reported a 52% drop in second-quarter net profit due to shipment delays caused by geopolitical issues. The company expects revenue growth in the second half of fiscal 2027 from its biosimilars and insulin demand. Launches of pertuzumab in Europe and Brazil are anticipated soon, contributing to this growth. In the US market, their ustekinumab biosimilar has gained significant market share, boosting prospects.
US Midterm Elections 2026: Gas prices hit record $4.12 per gallon on Election Day as Americans head to polls
Gas prices today: US voters faced record-high fuel prices on Election Day, with average gasoline prices reaching $4.12 per gallon and diesel hitting $6.28. Rising fuel, grocery and housing costs have become key concerns as Americans vote to decide control of Congress, with more than 60 million ballots already cast before polls opened.
Alkem Laboratories appoints Amrut Naik as CEO
Alkem Laboratories announced the appointment of Amrut Naik as its new Chief Executive Officer. His appointment is effective from November 11, following board approval and nomination committee recommendations. Naik has more than 26 years of experience in various areas, including pharmaceuticals and biologics. He holds both a bachelor's and master's degree in pharmaceutical science alongside a PhD in pharmacology.
Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 crore
Emcure Pharmaceuticals shares rose up to 7.3% after the company reported a 29.3% year-on-year increase in Q2 FY27 profit to Rs 325.1 crore. Revenue grew 24.3%, while EBITDA rose 30.9%, supported by strong international business growth.
Beyond tech: Kotak MF’s Shibani Kurian on India’s next innovation-led winners
Innovation-led investment opportunities in India are extending well beyond technology, with healthcare, auto components and industrials emerging as key areas of interest, according to Shibani Kurian, Head of Equity Research and Senior Fund Manager at Kotak Mahindra AMC. “Innovation can be seen across sectors and not necessarily limited to technology,” she said.
US midterm elections: Trump approval stuck near record low as voters lean towards Democrats, poll shows
US President Donald Trump's approval rating remains low as voters indicate their intention to oppose him in upcoming elections. Polls show that 46% of voters prefer Democrats compared to 38% for Republicans. Many voters identify rising living costs as a significant issue influencing their decisions. Democratic voters express greater enthusiasm about voting compared to their Republican counterparts. The general election outcomes are expected to reflect these sentiments among the electorate.
Sun Pharma’s specialty portfolio, Organon deal to drive growth
Sun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines. The company anticipates medium-term growth from therapies like Ilumya and ongoing innovative projects. Although profitability was affected by acquisition and litigation costs, the domestic market share increased to 8.6% from last year. R&D investments are expected to rise in the second half of FY27 as development accelerates.
India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugs
Over the past four quarters, India's medicine sales have increased significantly due to rising demand in chronic care segments. The growth rate reached 12% year-on-year in the September quarter, showing a positive trend in the industry. Larger pharmaceutical companies have benefited from the shutdown of many non-compliant smaller units. Budgets were also boosted by a reduction in GST on medicines.
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%
The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
Time to be be cautious in the market, convinced about the business: 5 large-cap stocks with upside potential of up to 22%
This is the time to focus on businesses that have lived through storms like this before and come out the other side. The large, proven names are where quality is to be found, and they have lagged badly enough that the odds are now tilting in their favour. Just wait for the mood to finally turn.
Sun Pharma Q2 profit takes a hit on exceptional items
Sun Pharmaceutical has seen a notable 36% drop in net profit, juxtaposed with an 11.8% rise in consolidated revenue. The uplift in revenue can be attributed largely to strong sales growth in India and emerging markets, particularly in domestic formulations. Conversely, US formulation sales faced a significant downturn. The company also marked progress in its integration planning for the acquisition of Organon, following the successful completion of regulatory approvals.
Sun Pharma Q2 profit falls 36% as litigation costs hit earnings
Sun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Revenue grew 11.8%, supported by strong domestic and emerging market sales, while US formulations weakened.
Sun Pharma books Rs 346 crore Organon deal costs in Q2; profit falls 36%
Sun Pharmaceutical Industries experienced a significant decline in net profit during the September quarter of FY27. The company incurred acquisition-related costs of Rs 346.16 crore while preparing for the Organon acquisition. Revenue from operations increased by 11.9% compared to the same quarter last year. An important settlement of Rs 922.67 crore was reached concerning a litigation in the US. The transaction with Organon is expected to close in Q4 FY27.
India’s drug pricing policy must balance affordability, medicine availability and pharma industry growth
The Government of India has recently capped trade margins on anti-cancer medicines at 30%. This decision has reignited the ongoing discussion about drug pricing and accessibility. The existing regulatory framework aims to provide affordable medicines while supporting the pharmaceutical industry. Ensuring pricing transparency and targeted interventions can help address excessive margins in the supply chain. The ultimate goal remains to enhance patients' access to quality medicines at reasonable prices.
Cancer drug price cuts leave costly brands untouched
Prices of several anti-cancer drugs are set to fall significantly starting November 9, offering some financial relief. However, the prices of top-selling patented treatments will remain unchanged after the revision by the NPPA. Generic cancer drugs will experience steep reductions, with some seeing over a 10-fold decrease in price. The Supreme Court is hearing petitions aimed at regulating high trade margins charged by hospitals.
Cancer care can be cheaper: 6 steps to cut drug costs
India has capped trade margins at 30% on 137 non-scheduled anti-cancer drugs to reduce treatment costs. Experts call for standardised care, quality checks, cost-effective medicines and pooled procurement to improve affordability.
Cipla’s US recovery, biosimilar pipeline key to future growth prospects
Cipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its strong India business and branded prescription therapies. Recent approvals for respiratory products and a growing biosimilar pipeline bolster Cipla's optimism for future growth. Despite declining operating margins, the firm anticipates improvements supported by product launches. Cipla remains focused on evaluating inorganic opportunities to enhance its specialty portfolio.
Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%
Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker North American sales. India revenue grew 12%, while US regulatory approval and a biosimilar partnership supported its product pipeline.
Cipla expects US business to draw support from upcoming product pipeline
Cipla reported a significant decline in its consolidated net profit for the second quarter of FY27. The company's North American revenue fell by 19% due to increased competition impacting sales of generic Revlimid. However, Cipla anticipates that its upcoming product pipeline will support performance in North America. In India, domestic revenue rose, providing some resilience amidst challenges in the US market.
Trump approval rises from record low to 32% ahead of midterm election, Reuters Ipsos poll finds
Donald Trump’s public approval rating rose by one percentage point to 32%, recovering slightly from a record low a week earlier, according to a Reuters/Ipsos poll. With the November 3 US midterm elections approaching, registered voters favoured Democrats over Republicans by 47% to 36% on the generic congressional ballot. The poll also found that Democrats led by nine percentage points after undecided voters were asked about their preferences.
Dr Reddy's bets on generic semaglutide, biosimilars
Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a focus on international markets. Furthermore, an expanding biosimilars portfolio aims to strengthen its position beyond traditional generics.
Load More
